Call End: American Tower Corporation (NYSE:AMT ) Nareit REITweek: 2025 Investor Conference June 04, 2025 11:00 AM ET Company Participants Steven O. Vondran - President, CEO & Director Conference Call Participants Richard Hamilton Prentiss - Raymond James & Associates, Inc., Research Division Richard Hamilton Prentiss All right.
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA's Breakthrough Therapy, RMAT, Fast-Track, and Orphan Drug status with Accelerated Approval via cUHDRS. Similarly, QURE is building MRI-guided infusion centers, payer-access teams, and a US Center of Excellence network. All of these moves prove management's high confidence in AMT-130.
AMT to gain from increased investments by wireless carriers in 4G and 5G networks. Solid business fundamentals and strategic capital allocation are add-ons.
Infrastructure is essential to everyday life for most of civilization, which can provide stability and predictable cash flows. We are looking at two different closed-end funds that provide diversified exposure to the rather broad infrastructure space. Both invest in infrastructure and even include global weightings; however, the strategies employed still differ, which can make them complementary holdings.
American Tower Corporation (NYSE:AMT ) Annual JPMorgan Global Technology, Media and Communications Conference May 13, 2025 10:50 AM ET Company Participants Steve Vondran - President and CEO Conference Call Participants Richard Cho - JPMorgan Richard Cho Hi. My name is Richard Cho.
American Tower benefits from strong secular trends in mobile data demand, 5G infrastructure expansion, and edge computing, driving robust top-and-bottom-line results. Despite recent sluggish stock performance, AMT's Q1 report highlights resilience with solid property revenues and AFFO growth, overcoming forex headwinds and the Sprint churn. AMT's dividend profile is impressive, with consistent growth and solid interest coverage, despite a modest yield compared to the sector median.
AMT's Q1 results reflect a year-over-year rise in revenues, led by property and service operations segment revenues. Strong organic tenant billing growth aids results.
While the top- and bottom-line numbers for American Tower (AMT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
American Tower Corporation (NYSE:AMT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Adam Smith - Senior Vice President, Investor Relations and FP&A Steve Vondran - President & Chief Executive Officer Rod Smith - Executive Vice President, Chief Financial Officer & Treasurer Conference Call Participants Matt Niknam - Deutsche Bank Jim Schneider - Goldman Sachs Ric Prentiss - Raymond James & Associates Michael Rollins - Citi Nick Del Deo - Moffett Nathanson Batya Levi - UBS Eric Luebchow - Wells Fargo Michael Funk - Bank of America Ben Swinburne - Morgan Stanley Jonathan Atkin - RBC Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the American Tower First Quarter 2025 Earnings Conference Call.
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for American Tower (AMT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Reflecting on past financial losses, I emphasize the importance of diversification to mitigate risks, as exemplified by my own experience with real estate investments. I advocate for a diversified investment portfolio, including REITs, BDCs, MLPs, Preferreds, Asset Managers, and Dividend Aristocrats, to ensure sustained high cash flow. Highlighting eight high-yielding REITs in the S&P 500, I provide insights into their performance, risks, and growth potential, emphasizing the need for diversification within the REIT sector.